- US Supreme Court’s second such ruling against Teva Pharmaceuticals’ interim injunction to revive its patent of on Copaxone (Glatiramer Acetate), a generic multiple sclerosis drug, could help generic companies like Hyderabad-based Natco to launch the drug in US.
- However, Natco, which has a tie up with US-based Mylan to market the generic version of Teva’s Copaxone, has decided to wait approvals from Mylan and USFDA before deciding on the launch.
- Teva’s Copaxone patents, which expire in September 2015, were held invalid by a US lower court enabling the generic entry this year when remaining patents expire as also allow it to be launched at risk.
- Copaxone registered sales of U $805 million in the U.S. in the December quarter and the U.S. market for it is about $3 billion.
- Read at: http://www.thehindu.com/todays-paper/tp-business/us-court-ruling-to-benefit-natco/article5935419.ece
- Natco Patent issues
- Generic Medicines